A Phase 4 interventional study of Abacavir/lamivudine and efavirenz and Tenofovir/Emtricitabine and efavirenz in Infection, Human Immunodeficiency Virus I and HIV Infection, sponsored by GlaxoSmithKline. Completed at 68 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-12.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing abacavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Abacavir · HIV Infections.
Among the 57 studies testing abacavir in HIV Infections, this one is the 9th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2007, is one of 13 in phase 4, and was the 48th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →1 of the 57 studies testing abacavir in HIV Infections is open now. Recruiting first, the newest first:
University College, London
Ages 4 wk–14 yrs
Abacavir: first FDA approval 1998 (ZIAGEN), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 392 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 78 across the 50 interventional studies. Of the 50 that completed or were terminated, 7 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 57 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 34th largest by enrollment of the 210 interventional ones that give a count, is one of 9 that started in 2007, is one of 18 in phase 4, and was the 120th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 57 studies testing abacavir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
Recently, the fixed-dose combinations (FDC) KIVEXA™ (abacavir/lamivudine) and TRUVADA (tenofovir disoproxil fumarate/emtricitabine) have facilitated the usage of once-daily regimens. However data from head-to-head randomized trials comparing these two FDCs as part of an initial regimen are not available at present. The long-term toxicity profiles of these regimens are of particular importance, as treatment of HIV is currently life-long and therefore, minimizing long-term toxicity and maximizing adherence and duration of regimen maintenance are critical therapy objectives.
The primary endpoint is estimated glomerular filtration rate (GFR), as measured by the modified diet in renal disease (MDRD) equation, a validated estimate of renal function.
ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
This study's enrollment of 392 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female is eligible to enter and participate in the study if she is of:
Complete abstinence from intercourse from 2 weeks prior to administration of the products, throughout the study, and for at least 2 weeks after discontinuation of all study medications Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide). Hormonal contraception will not be considered adequate for inclusion into this study Any intrauterine device (IUD) with published data showing that the expected failure rate is \<1% per year.
Sterilization (female subject or male partner of female subject).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abacavir/lamivudine and efavirenz
Drug: Tenofovir/Emtricitabine and efavirenz
Drug pages: Abacavir · Lamivudine · Efavirenz
Drug pages: Tenofovir · Emtricitabine · Efavirenz
Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48
Change from baseline was calculated as the Week 48 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine; BMI, body mass index.
Time frame: Baseline, Week 48
Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 24
Change from baseline was calculated as the Week 24 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine.
Time frame: Baseline, Week 24
Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 96
Change from baseline was calculated as the Week 96 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^s, meters squared; Scr, serum creatinine.
Time frame: Baseline, Week 96
Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 24
Change from baseline was calculated as the Week 24 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram; CG, Cockcroft-Gault.
Time frame: Baseline, Week 24
Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 48
Change from baseline was calculated as the Week 48 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram.
Time frame: Baseline, Week 48
Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 96
Change from baseline was calculated as the Week 96 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram.
Time frame: Baseline, Week 96
Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73 m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72 m^2, >=10%, and >=20% at Week 24
mL, milliliter; min, minute; m\^2, meters squared
Time frame: Baseline, Week 24
Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 48
mL, milliliter; min, minute; m\^2, meters squared
Time frame: Baseline, Week 48
Number of Participants With Decline From Baseline in Estimated GFR, Calculated by MDRD and Cockcroft-Gault Equations, of >=10 mL/Min/1.73m^2 (mL/Min for Cockcroft-Gault), >=20 mL/Min/1.72m^2, >=10%, and >=20% at Week 96
mL, milliliter; min, minute; m\^2, meters squared
Time frame: Baseline, Week 96
Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 24
Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.
Time frame: Baseline, Week 24
Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 48
Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.
Time frame: Baseline, Week 48
Number of Participants With National Kidney Foundation Chronic Kidney Disease Stage 1, 2, 3, 4, or 5 Categories of Renal Function at Week 96
Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.
Time frame: Baseline, Week 96
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24
BMD is a measure (grams \[g\] per centimeters cubed \[cm\^3\]) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
Time frame: Baseline, Week 24
Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24
BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
Time frame: Baseline, Week 24
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48
BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
Time frame: Baseline, Week 48
Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48
BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
Time frame: Baseline, Week 48
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96
BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
Time frame: Baseline, Week 96
Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96
BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
Time frame: Baseline, Week 96
Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 24
BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.
Time frame: Baseline, Week 24
Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 48
BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.
Time frame: Baseline, Week 48
Number of Participants With a Decline From Baseline in Lumbar Spine and Hip Bone Mineral Density (BMD) >=2.0% and >=6.0% at Week 96
BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.
Time frame: Baseline, Week 96
Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 24
The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.
Time frame: Week 24
Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 48
The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.
Time frame: Week 48
Number of Participants Meeting World Health Organization (WHO) Criteria for Osteopenia (T-score of -2.5 to -1.0) and Osteoporosis (T-score of <-2.5) at Week 96
The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.
Time frame: Week 96
Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 24
An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.
Time frame: Baseline to Week 24
Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 48
An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.
Time frame: Baseline to Week 48
Number of Participants Experiencing an Adverse Event (AE) Leading to Discontinuation by Week 96
An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.
Time frame: Baseline to Week 96
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 24
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.
Time frame: Baseline, Week 24
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 48
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.
Time frame: Baseline, Week 48
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Total Cholesterol at Week 96
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.
Time frame: Baseline, Week 96
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 24
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.
Time frame: Baseline, Week 24
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 48
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.
Time frame: Baseline, Week 48
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Low-density Lipoprotein (LDL) at Week 96
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.
Time frame: Baseline, Week 96
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 24
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.
Time frame: Baseline, Week 24
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 48
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.
Time frame: Baseline, Week 48
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting High-density Lipoprotein (HDL) at Week 96
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.
Time frame: Baseline, Week 96
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 24
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\<200 mg/dL, borderline high; 200-\<500 mg/dL, high; \>=500 mg/dL, very high.
Time frame: Baseline, Week 24
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 48
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\<200 mg/dL, borderline high; 200-\<500 mg/dL, high; \>=500 mg/dL, very high.
Time frame: Baseline, Week 48
Number of Participants With the Indicated Change From Baseline in National Cholesterol Education Program (NCEP) Thresholds for Fasting Triglycerides at Week 96
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\>200 mg/dL, borderline high; 200-\<500 mg/dL, high;\>= 500 mg/dL, very high.
Time frame: Baseline, Week 96
Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 24
The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug treatment.
Time frame: Week 24
Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 48
The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug treatment.
Time frame: Week 48
Number of Participants With the Indicated Treatment-emergent Division of AIDS (DAIDS) Toxicities at Week 96
The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug therapy.
Time frame: Week 96
Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 24
HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.
Time frame: Week 24
Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 48
HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.
Time frame: Week 48
Number of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) and 400 c/mL at Week 96
HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.
Time frame: Week 96
Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24
CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.
Time frame: Baseline, Week 24
Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48
CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.
Time frame: Baseline, Week 48
Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96
CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.
Time frame: Baseline, Week 96
Number of Participants Classified as Protocol-defined Failures With Treatment-emergent Resistance to Study Drug in the Indicated Viruses at Week 96
Viral resistance was measured using blood samples collected from participants throughout the study. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor. Virological failure was defined as any one of: participant does not achieve a 1 log10 copies (cop)/mL decrease in plasma HIV-1 RNA by Week (Wk) 4, or has two consecutive plasma HIV-1 RNA measures \>=400 cop/mL separated by at least 2-4 wk after being previously \<=400 cop/mL on/after Wk 4, or has two consecutive plasma HIV-1 RNA measures \>400 cop/mL separated by at least 2-4 wk on/after Wk 24.
Time frame: Week 96
Number of Participants Who Indicated "Yes" or "No" to the Question of Whether Unplanned Healthcare Resources Were Utilized
Participants were asked at each visit whether or not they utilized unplanned healthcare resources.
Time frame: Baseline to Week 96
Exploratory Analysis of Change From Baseline in Albumin as a Ratio to Urine Creatinine at Week 96
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline albumin value by the urine creatinine value. Albumin is measured in milligrams per millimole (mg/mmol).
Time frame: Baseline, Week 96
Exploratory Analysis of Change From Baseline in Beta 2 Microglobulin (B2M) as a Ratio to Urine Creatinine at Week 96
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline B2M value by the urine creatinine value. B2M, beta 2 microglobulin (measured in mg/mmol).
Time frame: Baseline, Week 96
Exploratory Analysis of Change From Baseline in N-acetyl-B-glucosaminidase (NAG) as a Ratio to Urine Creatinine at Week 96
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline NAG value by the urine creatinine value. NAG, N-acetyl-B-glucosaminidase (measured in micromoles per hour per millimole \[umol/h/mmol\]).
Time frame: Baseline, Week 96
Exploratory Analysis of Change From Baseline in Retinol Binding Protein (RBP) as a Ratio to Urine Creatinine at Week 96
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline RBP value by the urine creatinine value. RBP, retinol binding protein (measured in micrograms per millimole \[ug/mmol\]).
Time frame: Baseline, Week 96
Exploratory Analysis of Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) at Week 96
P1NP is a bone biomarker that was analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.
Time frame: Baseline, Week 96
Exploratory Analysis of Change From Baseline in Type 1 Collagen Cross-linked C-telopeptide at Week 96
Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.
Time frame: Baseline, Week 96
Exploratory Analysis of Change From Baseline in Osteocalcin at Week 96
Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.
Time frame: Baseline, Week 96
Exploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 96
Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.
Time frame: Baseline, Week 96
| Milestone | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Started | 195 | 197 |
| Completed | 115 | 134 |
| Not completed | 80 | 63 |
| Withdrew: Adverse event | 28 | 26 |
| Withdrew: Insufficient viral load response | 4 | 2 |
| Withdrew: Protocol-defined virological failure | 7 | 0 |
| Withdrew: Non-compliance | 2 | 4 |
| Withdrew: Lost to follow-up | 7 | 8 |
| Withdrew: Treatment eligibility criteria not met | 3 | 0 |
| Withdrew: Protocol violation | 7 | 2 |
| Withdrew: Investigator decision | 4 | 3 |
| Withdrew: Withdrawal by subject | 7 | 7 |
| Withdrew: Disease progression | 1 | 0 |
| Withdrew: Participant moved | 2 | 0 |
| Withdrew: Participant not able to perform week 96 | 1 | 0 |
| Withdrew: Participant moved.week 96 visit, no scan | 1 | 0 |
| Withdrew: Prohibited medication | 1 | 2 |
| Withdrew: Participant planning pregnancy | 1 | 0 |
| Withdrew: Participant overweight, no scan possible | 1 | 0 |
| Withdrew: No scan facilities | 0 | 2 |
| Withdrew: Pregnancy | 0 | 3 |
| Withdrew: Not exposed to study drug | 3 | 4 |
Change from baseline was calculated as the Week 48 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine; BMI, body mass index.
| milliliters per minute (mL/min)/1.73 m^2 | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 48 | 0.22 ± 0.890 | 1.18 ± 0.828 |
Change from baseline was calculated as the Week 24 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^2, meters squared; Scr, serum creatinine.
| mL/min/1.73m^2 | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 24 | 2.78 ± 0.884 | 0.43 ± 0.842 |
Change from baseline was calculated as the Week 96 value minus the baseline value. GFR is a measure of the rate at which blood is filtered by the kidney. MDRD is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and gender. GFR (mL/min/1.73 m\^2) = 175 \* (Scr)\^-1.154 \* (Age)\^-0.203 \* (0.742 if female) \* (1.212 if African American) (conventional units). mL, milliliters; min, minute; m\^s, meters squared; Scr, serum creatinine.
| mL/min/1.73m^2 | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Mean Change From Baseline in Estimated Glomerular Filtration Rate (GFR), Calculated by Modification of Diet in Renal Disease (MDRD) Equation, at Week 96 | 1.48 ± 1.022 | -1.15 ± 0.944 |
Change from baseline was calculated as the Week 24 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram; CG, Cockcroft-Gault.
| mL/min | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 24 | 4.27 ± 0.944 | 2.54 ± 0.897 |
Change from baseline was calculated as the Week 48 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram.
| mL/min | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 48 | 2.66 ± 1.005 | 3.80 ± 0.933 |
Change from baseline was calculated as the Week 96 value minus the baseline value. Cockcroft-Gault is an equation (calculation) used to estimate GFR based on serum creatinine, weight, and gender. GFR = (140 - age) \* (mass in kg) \* (0.85 if female) divided by 72 \* serum creatinine in mg/dL. mg, milligram; dL, deciliter; kg, kilogram.
| mL/min | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Mean Change From Baseline in Estimated GFR, Calculated by Cockcroft-Gault Equation, at Week 96 | 4.37 ± 1.228 | 2.68 ± 1.133 |
mL, milliliter; min, minute; m\^2, meters squared
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| >=10 mL/min, MDRD | 16 | 26 |
| >=10 mL/min, Cockcroft-Gault | 16 | 20 |
| >=20 mL/min, MDRD | 4 | 6 |
| >=20 mL/min, Cockcroft-Gault | 3 | 4 |
| >=10%, MDRD | 15 | 24 |
| >=10%, Cockcroft-Gault | 10 | 17 |
| >=20%, MDRD | 2 | 3 |
| >=20%, Cockcroft-Gault | 2 | 3 |
mL, milliliter; min, minute; m\^2, meters squared
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| >=10 mL/min, MDRD | 23 | 21 |
| >=10 mL/min, Cockcroft-Gault | 15 | 14 |
| >=20 mL/min, MDRD | 4 | 3 |
| >=20 mL/min, Cockcroft-Gault | 4 | 2 |
| >=10%, MDRD | 21 | 21 |
| >=10%, Cockcroft-Gault | 11 | 9 |
| >=20%, MDRD | 4 | 2 |
| >=20%, Cockcroft-Gault | 3 | 0 |
mL, milliliter; min, minute; m\^2, meters squared
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| >=10 mL/min, MDRD | 15 | 38 |
| >=10 mL/min, Cockcroft-Gault | 11 | 19 |
| >=20 mL/min, MDRD | 4 | 7 |
| >=20 mL/min, Cockcroft-Gault | 4 | 5 |
| >=10%, MDRD | 15 | 27 |
| >=10%, Cockcroft-Gault | 12 | 16 |
| >=20%, MDRD | 3 | 6 |
| >=20%, Cockcroft-Gault | 3 | 4 |
Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Normal | 97 | 114 |
| Stage 1 | 11 | 15 |
| Stage 2 | 5 | 5 |
| Stage 3 | 1 | 1 |
| Stage 4 | 0 | 0 |
| Stage 5 | 0 | 0 |
Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Missing | 12 | 19 |
| Normal | 90 | 106 |
| Stage 1 | 7 | 5 |
| Stage 2 | 3 | 3 |
| Stage 3 | 0 | 0 |
| Stage 4 | 0 | 0 |
| Stage 5 | 0 | 0 |
Normal: GFR \>=60 mL/min/1.73 m\^2 and creatinine ratio \<=200 mg/g GFR; Stage 1: GFR \>=90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 2: GFR \>=60-\<90 mL/min/1.73 m\^2 and creatinine ratio \>200 mg/g; Stage 3: GFR \>=30-\<60 mL/min/1.73 m\^2; Stage 4: GFR \>=15-\<30 mL/min/1.73 m\^2; Stage 5: GFR \<15 mL/min/1.73 m\^2. mL, milliliter; min, minute; m\^2, meters squared; mg, milligram; g, gram.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Missing | 11 | 18 |
| Normal | 75 | 83 |
| Stage 1 | 3 | 4 |
| Stage 2 | 4 | 4 |
| Stage 3 | 0 | 0 |
| Stage 4 | 0 | 0 |
| Stage 5 | 0 | 0 |
BMD is a measure (grams \[g\] per centimeters cubed \[cm\^3\]) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
| percent change | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24 | -2.12 ± 0.0011 | -3.30 ± 0.0011 |
BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
| percent change | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 24 | -1.19 ± 0.0007 | -2.73 ± 0.0007 |
BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
| percent change | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48 | -1.59 ± 0.0013 | -2.41 ± 0.0012 |
BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
| percent change | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 48 | -1.90 ± 0.0010 | -3.56 ± 0.0009 |
BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
| percent change | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96 | -0.87 ± 0.0017 | -1.70 ± 0.0015 |
BMD is a measure (grams per cm\^3) of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones. The standard error (SE) of both treatment groups was based on the model on the log scale.
| percent change | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Percent Change From Baseline in Hip Bone Mineral Density (BMD), Measured by Dual-energy X-ray Absorptiometry (DXA), at Week 96 | -2.17 ± 0.0013 | -3.55 ± 0.0012 |
BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| >=2%, spine, n=142, 165 | 73 | 115 |
| >=6%, spine, n=142, 165 | 10 | 17 |
| >=2%, hip, n=137, 160 | 38 | 93 |
| >=6%, hip, n=137, 160 | 1 | 6 |
BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| >=2%, spine, n=125, 141 | 51 | 84 |
| >=6%, spine, n=125, 141 | 5 | 13 |
| >=2%, hip, n=119, 140 | 54 | 111 |
| >=6%, hip, n=119, 140 | 3 | 17 |
BMD is a measure of the mineral content of bone in a particular skeletal area. DXA scans use low energy x-rays to measure the density of bones.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| >=2%, spine, n=59, 79 | 21 | 39 |
| >=6%, spine, n=59, 79 | 3 | 8 |
| >=2%, hip, n=58, 76 | 33 | 52 |
| >=6%, hip, n=58, 76 | 1 | 13 |
The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Osteopenia, spine, n=147, 173 | 41 | 68 |
| Osteporosis, spine, n=147, 173 | 16 | 9 |
| Osteopenia, hip, n=149, 170 | 38 | 54 |
| Osteoporosis, hip, n=149, 170 | 4 | 1 |
The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Osteopenia, spine, n=132, 147 | 41 | 57 |
| Osteporosis, spine, n=132, 147 | 15 | 5 |
| Osteopenia, hip, n=130, 147 | 37 | 50 |
| Osteoporosis, hip, n=130, 147 | 4 | 0 |
The T-score is a radiographic diagnosis that compares bone mineral density (BMD) to that of a "normal, healthy, 30-year-old female". The lower the T-score, the lower the BMD. A T-score of +1 to -1 is normal. A T-score decrease of -1 indicates a 10%-15% decrease in BMD.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Osteopenia, spine, n=64, 82 | 21 | 34 |
| Osteporosis, spine, n=64, 82 | 5 | 3 |
| Osteopenia, hip, n=65, 80 | 20 | 31 |
| Osteoporosis, hip, n=65, 80 | 0 | 0 |
An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Any event | 26 | 14 |
| Drug hypersensitivity | 11 | 1 |
| Rash | 2 | 3 |
| Dizziness | 0 | 2 |
| Hypersensitivity | 3 | 0 |
| Drug eruption | 1 | 1 |
An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Any event | 29 | 21 |
| Drug hypersensitivity | 11 | 1 |
| Bone density decreased | 0 | 2 |
| Rash | 2 | 3 |
| Dizziness | 1 | 3 |
| Hypersensitivity | 3 | 0 |
| Drug eruption | 1 | 1 |
An adverse event was any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events occurring in two or more participants are presented.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Any event | 33 | 28 |
| Drug hypersensitivity | 11 | 1 |
| Bone density decreased | 0 | 8 |
| Rash | 2 | 3 |
| Dizziness | 1 | 3 |
| Hypersensitivity | 3 | 0 |
| Abnormal dreams | 3 | 0 |
| Drug eruption | 1 | 1 |
| Depression | 0 | 2 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Desirable to desirable | 54 | 104 |
| Desirable to borderline high | 47 | 29 |
| Desirable to high | 32 | 9 |
| Borderline high to desirable | 1 | 3 |
| Borderline high to borderline high | 2 | 9 |
| Borderline high to high | 10 | 6 |
| High to desirable | 0 | 0 |
| High to borderline high | 0 | 0 |
| High to high | 3 | 2 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Desirable to desirable | 46 | 96 |
| Desirable to borderline high | 52 | 37 |
| Desirable to high | 36 | 9 |
| Borderline high to desirable | 1 | 1 |
| Borderline high to borderline high | 2 | 9 |
| Borderline high to high | 10 | 8 |
| High to desirable | 0 | 0 |
| High to borderline high | 0 | 0 |
| High to high | 3 | 2 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<200 mg/dL, desirable; 200-\<240 mg/dL, borderline high; \>=240 mg/dL, high. mg, milligram; dL, deciliter.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Desirable to desirable | 39 | 86 |
| Desirable to borderline high | 49 | 47 |
| Desirable to high | 46 | 10 |
| Borderline high to desirable | 1 | 1 |
| Borderline high to borderline high | 2 | 9 |
| Borderline high to high | 10 | 8 |
| High to desirable | 0 | 0 |
| High to borderline high | 0 | 0 |
| High to high | 3 | 2 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Optimal to optimal | 22 | 46 |
| Optimal to near or above optimal | 41 | 43 |
| Optimal to borderline high | 22 | 11 |
| Optimal to high | 6 | 1 |
| Optimal to very high | 1 | 0 |
| Near or above optimal to optimal | 0 | 5 |
| Near or above optimal to near or above optimal | 6 | 22 |
| Near or above optimal to borderline high | 17 | 11 |
| Near or above optimal to high | 12 | 5 |
| Near or above optimal to very high | 4 | 1 |
| Borderline high to optimal | 0 | 0 |
| Borderline high to near or above optimal | 1 | 6 |
| Borderline high to borderline high | 2 | 3 |
| Borderline high to high | 4 | 3 |
| Borderline high to very high | 3 | 2 |
| High to optimal | 0 | 0 |
| High to near or above optimal | 0 | 0 |
| High to borderline high | 0 | 0 |
| High to high | 1 | 1 |
| High to very high | 0 | 0 |
| Very high to optimal | 0 | 0 |
| Very high to near or above optimal | 0 | 0 |
| Very high to borderline high | 1 | 0 |
| Very high to high | 0 | 0 |
| Very high to very high | 1 | 1 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Optimal to optimal | 20 | 42 |
| Optimal to near or above optimal | 38 | 46 |
| Optimal to borderline high | 27 | 12 |
| Optimal to high | 8 | 1 |
| Optimal to very high | 1 | 0 |
| Near or above optimal to optimal | 0 | 3 |
| Near or above optimal to near or above optimal | 4 | 21 |
| Near or above optimal to borderline high | 19 | 13 |
| Near or above optimal to high | 12 | 6 |
| Near or above optimal to very high | 4 | 1 |
| Borderline high to optimal | 0 | 0 |
| Borderline high to near or above optimal | 1 | 3 |
| Borderline high to borderline high | 2 | 5 |
| Borderline high to high | 3 | 4 |
| Borderline high to very high | 4 | 2 |
| High to optimal | 0 | 0 |
| High to near or above optimal | 0 | 0 |
| High to borderline high | 0 | 0 |
| High to high | 1 | 1 |
| High to very high | 0 | 0 |
| Very high to optimal | 0 | 0 |
| Very high to near or above optimal | 0 | 0 |
| Very high to borderline high | 1 | 0 |
| Very high to high | 0 | 0 |
| Very high to very high | 1 | 1 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<100 mg/dL, optimal; 100-\<130 mg/dL, near/above optimal; 130-\<160 mg/dL, borderline high; 160-\<190 mg/dL, high; \>=190 mg/dL, very high.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Optimal to optimal | 18 | 37 |
| Optimal to near or above optimal | 35 | 46 |
| Optimal to borderline high | 29 | 17 |
| Optimal to high | 9 | 1 |
| Optimal to very high | 3 | 0 |
| Near or above optimal to optimal | 0 | 1 |
| Near or above optimal to near or above optimal | 4 | 19 |
| Near or above optimal to borderline high | 17 | 16 |
| Near or above optimal to high | 12 | 7 |
| Near or above optimal to very high | 6 | 2 |
| Borderline high to optimal | 0 | 0 |
| Borderline high to near or above optimal | 1 | 3 |
| Borderline high to borderline high | 2 | 5 |
| Borderline high to high | 3 | 3 |
| Borderline high to very high | 4 | 3 |
| High to optimal | 0 | 0 |
| High to near or above optimal | 0 | 0 |
| High to borderline high | 0 | 0 |
| High to high | 1 | 1 |
| High to very high | 0 | 0 |
| Very high to optimal | 0 | 0 |
| Very high to near or above optimal | 0 | 0 |
| Very high to borderline high | 1 | 0 |
| Very high to high | 0 | 0 |
| Very high to very high | 1 | 1 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Low to low | 19 | 36 |
| Low to normal | 72 | 66 |
| Low to high | 10 | 9 |
| Normal to low | 0 | 1 |
| Normal to normal | 12 | 30 |
| Normal to high | 26 | 12 |
| High to low | 0 | 0 |
| High to normal | 0 | 3 |
| High to high | 10 | 5 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Low to low | 17 | 28 |
| Low to normal | 67 | 73 |
| Low to high | 18 | 10 |
| Normal to low | 0 | 0 |
| Normal to normal | 11 | 23 |
| Normal to high | 27 | 20 |
| High to low | 0 | 0 |
| High to normal | 0 | 3 |
| High to high | 10 | 5 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<40 mg/dL, low; 40-\<60 mg/dL, normal; \>=60 mg/dL, high.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Low to low | 11 | 23 |
| Low to normal | 66 | 75 |
| Low to high | 25 | 13 |
| Normal to low | 0 | 0 |
| Normal to normal | 8 | 17 |
| Normal to high | 30 | 27 |
| High to low | 0 | 0 |
| High to normal | 0 | 1 |
| High to high | 10 | 7 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\<200 mg/dL, borderline high; 200-\<500 mg/dL, high; \>=500 mg/dL, very high.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Normal to normal | 63 | 78 |
| Normal to borderline high | 21 | 19 |
| Normal to high | 23 | 9 |
| Normal to very high | 0 | 0 |
| Borderline high to normal | 5 | 7 |
| Borderline high to borderline high | 5 | 10 |
| Borderline high to high | 9 | 15 |
| Borderline high to very high | 0 | 0 |
| High to normal | 2 | 6 |
| High to borderline high | 5 | 3 |
| High to high | 12 | 15 |
| High to very high | 3 | 0 |
| Very high to normal | 0 | 0 |
| Very high to borderline high | 0 | 0 |
| Very high to high | 0 | 1 |
| Very high to very high | 1 | 0 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\<200 mg/dL, borderline high; 200-\<500 mg/dL, high; \>=500 mg/dL, very high.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Normal to normal | 55 | 70 |
| Normal to borderline high | 22 | 23 |
| Normal to high | 30 | 12 |
| Normal to very high | 0 | 1 |
| Borderline high to normal | 4 | 6 |
| Borderline high to borderline high | 5 | 7 |
| Borderline high to high | 11 | 19 |
| Borderline high to very high | 0 | 0 |
| High to normal | 2 | 5 |
| High to borderline high | 4 | 3 |
| High to high | 12 | 15 |
| High to very high | 4 | 0 |
| Very high to normal | 0 | 0 |
| Very high to borderline high | 0 | 0 |
| Very high to high | 0 | 1 |
| Very high to very high | 1 | 0 |
Blood samples were collected from participants for analysis of their lipid profile. Data are categorized by the maximum post-baseline threshold reached. \<150 mg/dL, normal; 150-\>200 mg/dL, borderline high; 200-\<500 mg/dL, high;\>= 500 mg/dL, very high.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Normal to normal | 47 | 55 |
| Normal to borderline high | 25 | 31 |
| Normal to high | 34 | 20 |
| Normal to very high | 1 | 1 |
| Borderline high to normal | 4 | 5 |
| Borderline high to borderline high | 4 | 8 |
| Borderline high to high | 11 | 19 |
| Borderline high to very high | 1 | 0 |
| High to normal | 2 | 5 |
| High to borderline high | 4 | 2 |
| High to high | 11 | 16 |
| High to very high | 5 | 0 |
| Very high to normal | 0 | 0 |
| Very high to borderline high | 0 | 0 |
| Very high to high | 0 | 1 |
| Very high to very high | 1 | 0 |
The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug treatment.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Cholesterol, Grade 3 | 6 | 1 |
| Cholesterol, Grade 4 | 0 | 0 |
| LDL cholesterol, Grade 3 | 8 | 3 |
| LDL cholesterol, Grade 4 | 0 | 0 |
| Non-HDL cholesterol, Grade 3 | 19 | 5 |
| Non-HDL cholesterol, Grade 4 | 0 | 0 |
| Triglycerides, Grade 3 | 2 | 0 |
| Triglycerides, Grade 4 | 0 | 0 |
| Alanine aminotransferase, Grade 3 | 1 | 3 |
| Alanine aminotransferase, Grade 4 | 1 | 1 |
| Aspartate aminotransferase, Grade 3 | 1 | 0 |
| Aspartate aminotransferase, Grade 4 | 1 | 2 |
| Alkaline phosphatase, Grade 3 | 0 | 1 |
| Alkaline phosphatase, Grade 4 | 0 | 0 |
| Creatinine kinase, Grade 3 | 0 | 1 |
| Creatinine kinase, Grade 4 | 1 | 1 |
| Phosphorus inorganic, Grade 3 | 1 | 1 |
| Phosphorus inorganic, Grade 4 | 0 | 0 |
| Lipase, Grade 3 | 3 | 1 |
| Lipase, Grade 4 | 2 | 0 |
| Hyperkalaemia, Grade 3 | 0 | 0 |
| Hyperkalaemia, Grade 4 | 1 | 1 |
| Glomerular filtration rate, MDRD, Grade 3 | 1 | 1 |
| Glomerular filtration rate, MDRD, Grade 4 | 0 | 0 |
| Total neutrophils, Grade 3 | 1 | 0 |
| Total neutrophils, Grade 4 | 1 | 2 |
| Thrombocytopenia, Grade 3 | 1 | 0 |
| Thrombocytopenia, Grade 4 | 0 | 0 |
The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug treatment.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Cholesterol, Grade 3 | 7 | 1 |
| Cholesterol, Grade 4 | 0 | 0 |
| LDL cholesterol, Grade 3 | 9 | 3 |
| LDL cholesterol, Grade 4 | 0 | 0 |
| Non-HDL cholesterol, Grade 3 | 20 | 6 |
| Non-HDL cholesterol, Grade 4 | 0 | 0 |
| Triglycerides, Grade 3 | 3 | 0 |
| Triglycerides, Grade 4 | 0 | 0 |
| Alanine aminotransferase, Grade 3 | 2 | 4 |
| Alanine aminotransferase, Grade 4 | 2 | 1 |
| Aspartate aminotransferase, Grade 3 | 2 | 0 |
| Aspartate aminotransferase, Grade 4 | 2 | 2 |
| Alkaline phosphatase, Grade 3 | 0 | 1 |
| Alkaline phosphatase, Grade 4 | 0 | 0 |
| Total bilirubin Grade 3 | 1 | 0 |
| Total bilirubin, Grade 4 | 0 | 0 |
| Creatinine kinase, Grade 3 | 0 | 2 |
| Creatinine kinase, Grade 4 | 1 | 1 |
| Phosphorus inorganic, Grade 3 | 3 | 1 |
| Phosphorus inorganic, Grade 4 | 0 | 0 |
| Lipase, Grade 3 | 5 | 1 |
| Lipase, Grade 4 | 2 | 0 |
| Hyperkalaemia, Grade 3 | 0 | 0 |
| Hyperkalaemia, Grade 4 | 2 | 2 |
| Glomerular filtration rate, MDRD, Grade 3 | 1 | 1 |
| Glomerular filtration rate, MDRD, Grade 4 | 0 | 0 |
| Total neutrophils, Grade 3 | 2 | 0 |
| Total neutrophils, Grade 4 | 3 | 2 |
| Thrombocytopenia, Grade 4 | 1 | 0 |
| Thrombocytopenia, Grade 4 | 0 | 0 |
The DAIDS toxicity table provides descriptive terminology for grading the severity of adult adverse events. Laboratory grades also provide ranges for each parameter. Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening. LDL, low-density lipid; HDL, high-density lipid. Treatment emergent refers to any toxicity that was not present prior to the start of study drug therapy.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Cholesterol, Grade 3 | 9 | 1 |
| Cholesterol, Grade 4 | 0 | 0 |
| LDL cholesterol, Grade 3 | 13 | 5 |
| LDL cholesterol, Grade 4 | 0 | 0 |
| Non-HDL cholesterol, Grade 3 | 22 | 5 |
| Non-HDL cholesterol, Grade 4 | 0 | 0 |
| Triglycerides, Grade 3 | 2 | 0 |
| Triglycerides, Grade 4 | 1 | 0 |
| Alanine aminotransferase, Grade 3 | 2 | 4 |
| Alanine aminotransferase, Grade 4 | 2 | 1 |
| Aspartate aminotransferase, Grade 3 | 2 | 1 |
| Aspartate aminotransferase, Grade 4 | 2 | 2 |
| Alkaline phosphatase, Grade 3 | 0 | 1 |
| Alkaline phosphatase, Grade 4 | 0 | 0 |
| Total bilirubin, Grade 3 | 1 | 0 |
| Total bilirubin, Grade 4 | 0 | 0 |
| Creatinine kinase, Grade 3 | 0 | 2 |
| Creatinine kinase, Grade 4 | 1 | 2 |
| Phosphorus inorganic, Grade 3 | 4 | 3 |
| Phosphorus inorganic, Grade 4 | 0 | 0 |
| Lipase, Grade 3 | 6 | 2 |
| Lipase, Grade 4 | 4 | 2 |
| Hyperkalaemia, Grade 3 | 0 | 0 |
| Hyperkalaemia, Grade 4 | 2 | 0 |
| Glomerular filtration rate, MDRD, Grade 3 | 1 | 1 |
| Glomerular filtration rate, MDRD, Grade 4 | 0 | 0 |
| Total neutrophils, Grade 3 | 3 | 1 |
| Total neutrophils, Grade 4 | 5 | 3 |
| Thrombocytopenia, Grade 3 | 1 | 0 |
| Thrombocytopenia, Grade 4 | 0 | 0 |
HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| <50 copies/mL | 126 | 144 |
| <400 copies/mL | 147 | 168 |
HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| <50 copies/mL | 121 | 145 |
| <400 copies/mL | 130 | 151 |
HIV-1 RNA level (viral load) is a strong predictor of the rate of HIV disease progression. It was measured from plasma (participant blood samples) taken at all visits throughout the study. HIV, human immunodeficiency virus; RNA, ribonucleic acid. Viral load is a measure of the severity of the HIV infection.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| <50 copies/mL | 98 | 113 |
| <400 copies/mL | 110 | 126 |
CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.
| cells/millimeters cubed (mm^3) | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 24 | 110.0 (50.0 to 180.0) | 100.0 (45.0 to 150.0) |
CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.
| cells/mm^3 | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 48 | 150.0 (95.0 to 270.0) | 150.0 (80.0 to 215.0) |
CD4+ counts are used to monitor the progression of HIV disease and the strength of the immune system. The number of CD4+ cells decreases as HIV disease progresses. Cell counts were measured from participant blood samples taken throughout the study.
| cells/mm^3 | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Change From Baseline in Cluster Difference 4 (CD4+) Cell Count at Week 96 | 235.0 (130.0 to 390.0) | 220.0 (150.0 to 315.0) |
Viral resistance was measured using blood samples collected from participants throughout the study. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor. Virological failure was defined as any one of: participant does not achieve a 1 log10 copies (cop)/mL decrease in plasma HIV-1 RNA by Week (Wk) 4, or has two consecutive plasma HIV-1 RNA measures \>=400 cop/mL separated by at least 2-4 wk after being previously \<=400 cop/mL on/after Wk 4, or has two consecutive plasma HIV-1 RNA measures \>400 cop/mL separated by at least 2-4 wk on/after Wk 24.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Any treatment-emergent mutation | 4 | 0 |
| NRTI | 4 | 0 |
| NNRTI | 2 | 0 |
Participants were asked at each visit whether or not they utilized unplanned healthcare resources.
| participants | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Week 4, Yes, n=178, 183 | 60 | 49 |
| Week 4, No, n=178, 183 | 118 | 134 |
| Week 12, Yes, n=162, 177 | 56 | 47 |
| Week 12, No, n=162, 177 | 106 | 130 |
| Week 24, Yes, n=156, 173 | 70 | 59 |
| Week 24, No, n=156, 173 | 86 | 114 |
| Week 36, Yes, n=148, 169 | 48 | 50 |
| Week 36, No, n=148, 169 | 100 | 119 |
| Week 48, Yes, n=137, 161 | 44 | 36 |
| Week 48, No, n=137, 161 | 93 | 125 |
| Week 60, Yes, n=129, 148 | 47 | 44 |
| Week 60, No, n=129, 148 | 82 | 104 |
| Week 72, Yes, n=126, 139 | 48 | 40 |
| Week 72, No, n=126, 139 | 78 | 99 |
| Week 84, Yes, n=121, 136 | 34 | 24 |
| Week 84, No, n=121, 136 | 87 | 108 |
| Week 96, Yes, n=113, 135 | 30 | 17 |
| Week 96, No, n=113, 135 | 83 | 118 |
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline albumin value by the urine creatinine value. Albumin is measured in milligrams per millimole (mg/mmol).
| ratio | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Exploratory Analysis of Change From Baseline in Albumin as a Ratio to Urine Creatinine at Week 96 | 0.872 (0.716 to 1.062) | 0.973 (0.806 to 1.174) |
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline B2M value by the urine creatinine value. B2M, beta 2 microglobulin (measured in mg/mmol).
| ratio | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Exploratory Analysis of Change From Baseline in Beta 2 Microglobulin (B2M) as a Ratio to Urine Creatinine at Week 96 | 0.542 (0.370 to 0.792) | 0.984 (0.684 to 1.416) |
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline NAG value by the urine creatinine value. NAG, N-acetyl-B-glucosaminidase (measured in micromoles per hour per millimole \[umol/h/mmol\]).
| ratio | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Exploratory Analysis of Change From Baseline in N-acetyl-B-glucosaminidase (NAG) as a Ratio to Urine Creatinine at Week 96 | 0.868 (0.774 to 0.974) | 0.939 (0.844 to 1.044) |
Renal biomarkers were analyzed using urine samples collected from participants at baseline and Week 96. Renal biomarkers may be an indicator of various aspects of kidney function. The ratio was calculated by dividing the change from baseline RBP value by the urine creatinine value. RBP, retinol binding protein (measured in micrograms per millimole \[ug/mmol\]).
| ratio | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Exploratory Analysis of Change From Baseline in Retinol Binding Protein (RBP) as a Ratio to Urine Creatinine at Week 96 | 1.099 (0.882 to 1.369) | 1.550 (1.247 to 1.927) |
P1NP is a bone biomarker that was analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.
| micrograms per Liter (ug/L) | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Exploratory Analysis of Change From Baseline in Procollagen Type 1 Amino-terminal Propeptide (P1NP) at Week 96 | 1.2 (1.1 to 1.2) | 1.4 (1.3 to 1.5) |
Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.
| nanograms per Liter (ng/L) | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Exploratory Analysis of Change From Baseline in Type 1 Collagen Cross-linked C-telopeptide at Week 96 | 89.9 (25.1 to 154.7) | 203.6 (143.3 to 264.0) |
Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.
| ug/L | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Exploratory Analysis of Change From Baseline in Osteocalcin at Week 96 | 3.01 (0.87 to 5.14) | 5.79 (3.68 to 7.90) |
Bone biomarkers were analyzed using blood samples collected from participants at baseline and Week 96. Bone biomarkers may be an indicator of bone turnover.
| ug/L | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Exploratory Analysis of Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP) at Week 96 | 1.111 (-0.426 to 2.649) | 2.542 (1.028 to 4.056) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABC/3TC FDC | — | 31/192 (16.1%) | 172/192 (89.6%) |
| TDF/FTC FDC | — | 20/193 (10.4%) | 175/193 (90.7%) |
| Event | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| Drug hypersensitivityImmune system disorders | 5/192 | 1/193 |
| PneumoniaInfections and infestations | 5/192 | 1/193 |
| HypersensitivityImmune system disorders | 3/192 | 0/193 |
| GastroenteritisInfections and infestations | 2/192 | 0/193 |
| Immune reconstitution syndromeImmune system disorders | 2/192 | 0/193 |
| Lower respiratory tract infectionInfections and infestations | 1/192 | 1/193 |
| Pulmonary tuberculosisInfections and infestations | 1/192 | 1/193 |
| ErysipelasInfections and infestations | 1/192 | 0/193 |
| Eye infection toxoplasmalInfections and infestations | 1/192 | 0/193 |
| Herpes ZosterInfections and infestations | 1/192 | 0/193 |
| Event | ABC/3TC FDC | TDF/FTC FDC |
|---|---|---|
| DizzinessNervous system disorders | 48/192 | 48/193 |
| NasopharyngitisInfections and infestations | 39/192 | 36/193 |
| DiarrhoeaGastrointestinal disorders | 36/192 | 27/193 |
| HeadacheNervous system disorders | 17/192 | 29/193 |
| Abnormal dreamsPsychiatric disorders | 23/192 | 22/193 |
| InsomniaPsychiatric disorders | 21/192 | 18/193 |
| RashSkin and subcutaneous tissue disorders | 18/192 | 20/193 |
| NauseaGastrointestinal disorders | 17/192 | 16/193 |
| CoughRespiratory, thoracic and mediastinal disorders | 17/192 | 13/193 |
| Sleep disorderPsychiatric disorders | 14/192 | 16/193 |
| Age Continuous(Years) | ABC/3TC FDC | TDF/FTC FDC | Total |
|---|---|---|---|
| Median | 38.0 (19 to 70) | 36.0 (18 to 66) | 37.0 (18 to 70) |
| Sex: Female, Male(Participants) | ABC/3TC FDC | TDF/FTC FDC | Total |
|---|---|---|---|
| Female | 33 | 40 | 73 |
| Male | 159 | 153 | 312 |
| Race/Ethnicity, Customized(participants) | ABC/3TC FDC | TDF/FTC FDC | Total |
|---|---|---|---|
| African American/African Heritage | 26 | 30 | 56 |
| American Indian or Alaska Native | 11 | 7 | 18 |
| Asian | 2 | 5 | 7 |
| White | 153 | 151 | 304 |
The record gives a start of Jun 2007, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abacavir · Lamivudine · Efavirenz